In reply [11]

Journal of Clinical Oncology

Volumn 25, Issue 33, 2007, Pages 5334-5335

  Ratain, Mark J ^a   Cohen, Ezra E W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAPATINIB;

BREAST CANCER; CARDIOVASCULAR RISK; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HUMAN; LETTER; PRIORITY JOURNAL; QT PROLONGATION; UNITED STATES;

EID: 36849016272     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.9212     Document Type: Letter

References (4)

1. Center for Drug Evaluation and Research: Application 22-059. http://www.fda.gov/cder/foi/nda/2007/022059s000_ClinPharmR.pdf
2. Kannankeril PJ, Roden DM: Drug-induced long QT and torsade de pointes: Recent advances. Curr Opin Cardiol 22:39-43, 2007
3. Stone VE, Hogan JW, Schuman P, et al: Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the her study. J Acquir Immune Defic Syndr 28:124-131, 2001
4. Barton JH, Emanuel EJ: The patents-based pharmaceutical development process: Rationale, problems, and potential reforms. JAMA 294:2075-2082, 2005